Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT: Rivastigmine patch in Alzheimer's Disease
NCT00561392Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Primary completion
- Nov 2008
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Primary endpoints: Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Who Completed the Study, Percentage of Participants Treated by Rivastigmine 10 cm^2 Patch for at Least 8 Weeks Regardless Whether They Completed the Study and 1 more. Started Nov 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00561392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561392.